Citracal ad claims
This article was originally published in The Tan Sheet
Executive Summary
National Advertising Division of the Council of Better Business Bureaus concludes unqualified marketing claims that Mission Pharmacal's Citracal is "better absorbed than calcium carbonate" should be discontinued. Group also found superior solubility claims made in the absence of superior absorption statements would be supported by the firm's in vitro data if "carefully qualified." Concluded May 5, inquiry was prompted by GlaxoSmithKline, marketer of OsCal supplements with calcium carbonate. NAD's recommendations reflect and confirm January decision by National Advertising Review Board regarding similar Citracal claims and supporting data. That case involved a challenge by Caltrate marketer Wyeth Consumer Healthcare (1"The Tan Sheet" Aug. 5, 2002, p. 7)...
You may also be interested in...
Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD
Quantified claims that Mission Pharmacal's Citracal calcium supplement is better absorbed than calcium carbonate are not supported by the submitted clinical trials and should be discontinued, NAD concludes in an upcoming NAD Case Reports
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.